Seralutinib New Drug Application Submitted to the FDA for Pulmonary Arterial Hypertension – Gossamer Bio
Gossamer Bio, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatment… read more.
